Comprehensive quality evaluation requires all of these tests, not just the headline purity number
GLP-1 patches are not currently available to patients, but research is underway
Pigmented lesions of the genital mucosa
mostly mildmoderate GI events with low discontinuation Next steps: Phase 3 obesity program (Enith1/Enith2) to start this quarter Optionality: Potential combination use with petrelintide Why it matters: Puts Genentech firmly on the obesity map with top-tier efficacy Competitive with tirzepatide (~1522% in Phase 3) and clearly ahead of semaglutide (~1517%) Enters a crowded field where convenience (orals like oral Wegovy, orforglipron) and durability + tolerability will decide winners Key Takeaway: CT-388s Phase 2 results position it as a serious challenger in dual-agonist obesity therapy
The analysis included 10,997 adults with CM initiating a GLP-1 RA (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or albiglutide) within 12 months of diagnosis, as well as matched adults initiating topiramate.The researchers found that compared with topiramate, GLP-1 RA initiators had a lower risk for emergency department visits (risk ratio [RR], 0.90), hospitalizations (RR, 0.86), nerve blocks (RR, 0.87), and triptan use (RR, 0.87)
Anxiety and stress can lead to emotional or stress eating, which may nullify the effect of semaglutide
